Key result
Recent 2020 updates in peripheral artery disease management highlight the efficacy of drug-coated devices for femoropopliteal lesions, ongoing safety evaluations of paclitaxel, and new antithrombotic regimens.
Why the study?
PAD patients are increasing with population aging and Westernized diet, requiring multidisciplinary management, motivating an update on 2020 PAD treatment.
Answers are grounded in this paper and cite their sources.
Should not yet alter PAD management; leaves open need for randomized confirmation of drug-coated device benefits.
は じ め に 近年,食生活の欧米化に加え,高齢化社会が進行し, Peripheral Artery Disease(PAD)患者が増加の一途を 辿っている.PAD の Risk factor は加齢,喫煙,糖尿病, 高血圧,脂質異常症,透析などであり,動脈硬化は全身の 血管に進行することから Polyvascular diseaseの概念が浸 透するとともに,下肢重症虚血においては包括的高度慢性 下肢虚血(Chronic limb-threatening ischemia, CLTI)の概 念も導入された.さらには PAD患者において Minor amputationを施行した場合,その予後は多くの悪性腫瘍の生 存率よりも悪いと報告されるように,集学的・包括的な 管理がきわめて重要である.本稿では,2020年度の PAD 治療の updateを総大腿動脈病変,大腿膝窩動脈病変,膝 下動脈病変に分けて概説するとともに,近年話題のパクリ タキセル問題,薬物運動療法にも言及する.
No takes yet. Share an insight, caveat, or question.
Baba et al. (2021) conducted a review in Peripheral Artery Disease. Peripheral Artery Disease treatments (endovascular therapy, paclitaxel-coated devices, bypass, antithrombotic therapy) was evaluated. Recent 2020 updates in peripheral artery disease management highlight the efficacy of drug-coated devices for femoropopliteal lesions, ongoing safety evaluations of paclitaxel, and new antithrombotic regimens.
Synapse has enriched 10 related papers. Consider them for comparative context: